BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd boosted its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 56.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 137,675 shares of the biotechnology company’s stock after purchasing an additional 49,534 shares during the quarter. Mediolanum International Funds Ltd owned approximately 0.07% of BioMarin Pharmaceutical worth $7,437,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in BMRN. Transcend Capital Advisors LLC grew its position in shares of BioMarin Pharmaceutical by 22.8% during the third quarter. Transcend Capital Advisors LLC now owns 4,827 shares of the biotechnology company’s stock worth $261,000 after buying an additional 895 shares in the last quarter. National Pension Service boosted its stake in BioMarin Pharmaceutical by 47.1% during the 3rd quarter. National Pension Service now owns 20,412 shares of the biotechnology company’s stock valued at $1,106,000 after acquiring an additional 6,534 shares during the last quarter. Arizona State Retirement System grew its holdings in BioMarin Pharmaceutical by 1.3% during the 3rd quarter. Arizona State Retirement System now owns 56,734 shares of the biotechnology company’s stock worth $3,073,000 after acquiring an additional 716 shares in the last quarter. SYM FINANCIAL Corp acquired a new position in BioMarin Pharmaceutical during the 3rd quarter worth $249,000. Finally, AE Wealth Management LLC bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth about $285,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Price Performance

Shares of BMRN opened at $57.95 on Tuesday. BioMarin Pharmaceutical Inc. has a 12 month low of $50.76 and a 12 month high of $73.51. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. The stock has a fifty day moving average price of $56.56 and a 200 day moving average price of $55.94. The company has a market cap of $11.13 billion, a P/E ratio of 21.79, a PEG ratio of 0.62 and a beta of 0.26.

Analyst Ratings Changes

BMRN has been the topic of several research analyst reports. Morgan Stanley reduced their price target on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Tudor Pickering set a $88.00 price objective on BioMarin Pharmaceutical in a research note on Monday, November 3rd. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Sanford C. Bernstein lowered their price target on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Finally, Wells Fargo & Company dropped their price target on BioMarin Pharmaceutical from $90.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 28th. Seventeen investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.04.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.